Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
about
Toxicity management of immunotherapy for patients with metastatic melanomaIpilimumab and its toxicities: a multidisciplinary approachGastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Emerging immunotherapies for glioblastomaEmerging options for the treatment of melanoma - focus on ipilimumab.Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterColonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.Ipilimumab in the treatment of melanoma.Colitis associated with biological agentsSevere adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.The management of immunosuppression in patients with inflammatory bowel disease and cancer.Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.Systematic review: colitis associated with anti-CTLA-4 therapy.The emerging role of immune checkpoint inhibition in malignant lymphoma.An Overview of the Innate and Adaptive Immune System in Inflammatory Bowel Disease.Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.Infliximab for ipilimumab-induced colitis: A series of 13 patients.Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.Ipilimumab-associated colitis or refractory Clostridium difficile infection?Acute visual loss after ipilimumab treatment for metastatic melanoma.Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab.Ipilimumab-induced perforating colitis.Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.Clinical assessment of immune-related adverse events.Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two casesSerious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse eventsInfliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
P2860
Q26738662-577BC761-9A36-4D2C-BD93-C67F88ECBDD0Q33777476-49AC6CCD-C3FC-47F8-8F42-9AF5347BB7E5Q36260666-C4B1A48A-F8A8-4525-8AC2-4F6AD80691A9Q36522770-79F4DD35-31C6-41AA-845C-1FA738F87962Q37025105-3716C6BE-F559-446E-9EE4-07B54C6C8A5FQ37031656-ADCFE643-AAD7-41FE-9503-8E609ACD365DQ37380454-D4772520-C4F0-4544-AC47-F7822BF93AB6Q37714359-8F26F97E-7FE0-48B4-9C58-B459E120A35BQ38002493-55CEF1D3-3010-4C06-9BB3-035E00FDCC39Q38007938-7C3B4AD2-9C0C-4D24-A5F8-5152FDB3C128Q38114116-5286567D-93CE-4C09-9089-8C9FA8F1785AQ38125570-769098A6-CB08-4B00-8B75-57A5595FA6A6Q38364937-14F7A6F9-6291-48AD-B0C7-CCF6002B46A9Q38529051-5B810461-4687-426C-B173-D726811E32BBQ38791036-5AE1B743-AE5D-4752-8870-D604B3396537Q38990222-AF7FCE8E-FF7D-4638-9D32-4CC879CC0B78Q39021248-17447A04-0B1D-4ED6-9CEC-0DFC7B326CECQ39040949-C2D236EE-67B5-4B72-8C3E-71CA4C1EFE65Q39328076-6614DBBE-8A32-4887-8A02-31E1F99B5959Q41110062-870B80E3-2B2E-4C61-8591-26F71FC25EAEQ41485806-4CC17647-EB27-4293-ABC6-C474700434FEQ41826015-36206A28-13AB-4794-9A44-B13166F3B34CQ43065896-EC3024EF-CA44-46A9-89A9-C70A2DEC7475Q43532238-35B13B04-1821-4EC0-AB30-FA3798F43FBAQ47397659-ED90649A-011F-4378-B852-B337FC04EEB9Q50653513-CE50E1EE-A6AB-4357-B4F3-3F2DCABDAA16Q50719439-54B35466-D697-45CA-8C01-D60131EF5462Q55292659-9554E254-C3E5-4C1F-B398-9771D36BE47FQ56889672-8C0D833B-6DD6-482A-91F3-538951AE79D2Q57038250-E99D405E-58D5-4419-A94B-87B8430CCB54Q57280953-C78D5D58-1A21-4CFE-A785-4D226BA1C06CQ58698500-E650E942-9F93-4D91-A2E7-69C67CB07ED2
P2860
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@en
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@nl
type
label
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@en
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@nl
prefLabel
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@en
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@nl
P2093
P1476
Cytotoxic T-lymphocyte-associa ...... ts management with infliximab.
@en
P2093
J S Barkin
R L Johnston
P2888
P304
P356
10.1007/S10620-008-0641-Z
P577
2008-12-23T00:00:00Z